http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kim, Heejung,Huh, Jeongsoon,Jeon, Hyunchu,Choi, Daekyu,Han, Jungoh,Kim, Youngmi,Jung, Yunjin Wiley Subscription Services, Inc., A Wiley Company 2009 journal of pharmaceutical sciences Vol.98 No.1
<P><B>Abstract</B></P><P>To evaluate <I>N</I>,<I>N</I>′‐bis(5‐aminosalicyl)‐<SMALL>L</SMALL>‐cystine (5‐ASA‐Cys) as a potential colon‐specific 5‐aminosalicylic acid prodrug with dual therapeutic effects in experimental colitis, the pharmacokinetics and therapeutic activity were investigated after oral administration of 5‐ASA‐Cys and amelioration of experimental colitis was compared after rectal administration of 5‐aminosalicylic acid (5‐ASA) and/or cysteine. In addition, the gluthathione (GSH) level in the inflamed colonic tissue was examined after administration of cysteine or 5‐ASA‐Cys. Oral administration of 5‐ASA‐Cys delivered much greater amount of 5‐ASA to the large intestine and excreted lower amount of 5‐ASA via urine than that of free 5‐ASA. Oral administration of 5‐ASA‐Cys ameliorated experimental colitis of rats induced by TNBS, which was more effective than that of sulfasalazine. Although cysteine administered rectally was not significantly effective, intracolonic treatment with both 5‐ASA and cysteine showed a synergic effect in alleviating the rat colitis. Furthermore, not only 5‐ASA‐Cys administered orally but also cysteine administered rectally increased the glutathione level in the inflamed colonic tissue. Taken together, these results suggest that 5‐ASA‐Cys is a potential colon specific 5‐ASA prodrug with dual therapeutic effects on experimental colitis and cysteine modulation of the glutathione level may be relevant to the dual effects of the prodrug. © 2008 Wiley‐Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:159–168, 2009</P>
Kim, Heejung,Kim, Duksoo,Choi, Daekyu,Jeon, Hyunchu,Han, Jungoh,Jung, Yunjin,Kong, Hyesik,Kim, Young Mi Informa Healthcare 2008 DRUG DELIVERY Vol.15 No.1
<P> N,N'-bis(5-aminosalicyl)-L-cystine (5-ASA-Cys) was prepared by a simple synthetic route. 5-ASA-Cys was not degraded in pH 1.2 and 6.8 buffer solutions, and in the homogenates of the upper intestine. In marked contrast, 5-ASA-Cys was deconjugated extensively to liberate 5-ASA in the cecal contents. Upon oral administration of 5-ASA-Cys to rats, the plasma concentration of 5-ASA-Cys was extremely low and the urinary recovery of 5-ASA-Cys was ∼ 10% of the dose. These results suggest that 5-ASA-Cys administered orally is delivered efficiently to the large intestine followed by deconjugation to liberate 5-ASA and cystine.</P>